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Summary The effects of neurotensin on the incidence, number, size, and histology of colon tumours induced
by azoxymethane (AOM) were investigated in Wistar rats. Rats were given 10 weekly injections of AOM
(7.4 mg kg- ' body weight) and were also given 200Pg kg-' of neurotensin in depot form every other day until
the end of the experiment. In week 40, prolonged alternate-day administration of neurotensin resulted in
significant increases in the number and size of colon tumours and the incidence of adenocarcinomas
penetrating muscle layer and deeper. However, neurotensin did not influence the incidence of tumour-bearing
rats and the histological appearance of colon tumours. Administration of neurotensin caused a significant
increase in the labelling index of the colon cancers but not that of colon mucosa. These findings indicate that
neurotensin enhanced the growth of colon tumours, possibly related to its effect in incre-asing proliferation of
colon cancer cells.
Neurotensin is an endogenous tridecapeptide, initially dis-
covered in bovine hypothalamus (Carraway & Leeman, 1978;
Carraway et al., 1978) and subsequently found to be widely
distributed in the gastrointestinal tract (Polak et al., 1977).
Among the gastrointestinal responses to intravenous
challenge with neurotensin are decreased gastrointestinal
motility, increased blood flow, decreased gastric acid and
pepsin secretion, and hyperglycaemia (Walsh, 1987). We
recently found that prolonged alternate-day administration of
neurotensin significantly increased the incidence of gastric
cancer induced in rats by N-methyl-N'-nitro-N-nitrosoguani-
dine (Tatsuta et al., 1989). Furthermore, neurotensin recep-
tors were found in a human colon adenocarcinoma cell line
(Amar et al., 1986). These findings suggest that neurotensin
affects the growth of colon cancers. Therefore, in the present
work, we examined its effect on the development of colon
cancer by treating rats with neurotensin from the beginning
of azoxymethane (AOM) treatment.
Materials and methods
Animals
A total of 60 young (6-week-old) male Wistar rats were used
in this study. Animals were purchased from SLC (Shizuoka,
Japan). The rats were housed in suspended wire-bottomed
metal cages in animal quarters with controlled temperature
(21-22°C), humidity (30-50%), and light (12-h cycle), and
had free access to normal tap water and regular chow pellets
(Oriental Yeast, Tokyo, Japan).
Carcinogen and treatment
Rats were divided randomly into two groups and treated as
follows. Group 1 (30 rats) was given 10 weekly subcutaneous
injections of AOM (7.4 mg kg-' body weight; Sigma, St
Louis, MO) in 0.9% NaCl solution, and also received
neurotensin (Peptide Institute, Osaka) every other day at a
dose of 200 pg kg-' body weight. Neurotensin was injected as
a suspension in olive oil to prolong its effect. Injections were
given subcutaneously in a volume of 2 ml kg-' until the end
of the experiment at week 40, between 2 and 3 p.m. on each
day, various sites of injection being chosen. Group 2 (30 rats)
was given AOM for 10 weeks in the same way as Group 1
and also received the vehicle, plain olive oil.
Tissue sampling
Animals that survived for more than 31 weeks were included
in the effective numbers because the first tumour of the colon
was found in a rat from Group 1 that died in week 31. Rats
were sacrificed when they became moribund, and surviving
animals were sacrificed at the end of Week 40.
Rats sacrificed during the experimental period were
autopsied. The large intestine was opened, pinned flat on a
cork mat, and fixed with buffered picric acid-formaldehyde
solution (Stefanini et al., 1967). The fixed colon was cut into
5 segments of equal length, which are referred to hereafter as
Part 1 (adjacent to the anal orifice) to Part 5 (adjacent to the
caecum). Tumour-bearing areas and areas suspected of hav-
ing lesions were dissected and embedded in paraffin.
Semiserial sections 5 gm thick were cut from each block to
expose the central part of the tumour, or the stalk, and to
determine the extent of the tumour, and were stained with
hematoxylin and eosin. In addition to tumours, flat mucosa
of the fixed colon with no visible tumours from each segment
was cut into 2 strips 3 mm wide, which were embedded in
paraffin. Thin semiserial sections from each block were
prepared and were inspected microscopically for tumour foci.
Sections were examined without knowledge of the treatment.
The maximum size of the colon tumour was measured on the
Xerox copy of the resected colon after histological examina-
tions of the semiserial sections.
Histological classification ofcolon tumours
Histologically, colon tumours were defined as neoplastic pro-
liferations of epithelial origin. As previously reported (Sunter
et al., 1978), colon tumours were classified into 4 types:
adenoma, bearing a striking resemblance to the adenomata
seen in the human colon; Group 1 carcinoma, showing
localised invasion into and through the muscularis mucosae;
Group 2 carcinoma, being frankly invasive adenocarcinoma,
well differentiated or moderately well differentiated, with
extensive invasion of the bowel wall; and Group 3 car-
cinoma, the appearance being that of poorly differentiated
mucin-secreting adenocarcinoma, frequently invading through
the full thickness of the bowel wall.
Measurement ofserum gastrin level
Serum gastrin levels were determined in experimental weeks 9
and 40. For this, rats were fasted for 12 h and then received
the following subcutaneous injections: Group 1, neurotensin,
200 pg kg-'; Group 2, olive oil, 2 ml kg-'. One hour later the
animals were anaesthetised and blood was obtained by car-
diac puncture. The serum was separated and stored at
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- 20°C for not more than 1 week. Its gastrin content was
assayed with a radioimmunoassay kit from Dainabot Radio-
isotope Laboratories (Tokyo, Japan) (Tatsuta et al., 1977).
This gastrin kit was validated for rat gastrin (linuma et al.,
1982).
Labelling indices ofcolon mucosa and cancers
The labelling indices of colon mucosa and/or colon cancers
were measured in weeks 9 and 40 with an immunohisto-
chemical analysis kit for assaying bromodeoxyuridine (BrdU)
incorporation (Becton-Dickinson Immunocytometry System,
Mountain View, CA) (Gratzner, 1982; Morstyn et al., 1983),
by the modified method described by Tada et al. (1985).
Briefly, the rats were fasted for 12 h and then received the
following subcutaneous injections: Group 1, neurotensin,
200Lg kg-'; Group 2, olive oil, 2 ml kg-'. In week 9, olive
oil or neurotensin was administered 12 h after injection of the
carcinogen. One hour later the rats received an intra-
peritoneal injection of BrdU, 20 mg kg-' body weight, and
were sacrificed 1 h later with ether. The colon was fixed in
70% ethanol for 4 h. Parts 2 (distal portion) and 4 (proximal
portion) of the colon were then excised and embedded in
paraffin. Sections 3 ytm thick were immersed in 2 N HCI solu-
tion for 30 min at room temperature, and then in 0.1 M
Na2B407 to neutralise the acid. Slides were immersed in
methanol containing 3% H202 for 30 min and then treated
with 10% porcine serum. The specimens were stained with
anti-BrdU monoclonal antibody (dilution 1:100) for 2 h at
room temperature, washed, stained with biotin-conjugated
horse anti-mouse antibody (dilution 1:200) for 30 min, and
stained with avidin-biotin-peroxidase complex for 30 min.
The reaction product was located with 3,3'-diaminobenzidine
tetrahydrochloride. Cells that contained BrdU were identified
by the presence of a dark pigment over their nuclei.
To analyse the labelling indices of the colon mucosa, the
numbers of BrdU-labelled and unlabelled cells in the zone of
proliferating cells were counted (Eastwood & Quimby, 1983)
without knowledge of which treatment group the samples
were from. The zone of proliferating cells was defined as all
cells below the highest labelled cells. We selected 100 well-
oriented columns of pits and glands in each rat. For analysis
of the labelling index of colon cancers, the number of BrdU-
labelled and unlabelled cancer cells in the colon cancer
lesions were counted. We selected 1,000, or more, cancer cells
in the peripheral zone of the tumour. On the basis of these
measurements, we derived the labelling index (number of
BrdU-labelled cells/total number of cells within the zone of
proliferation or colon cancer lesion).
Apoptotic index ofcolon cancers
The apoptotic index of Group 2 carcinomas was measured in
week 40. Apoptotic cells were characterised by loss ofcontact
with neighbouring cells, pyknosis and cytoplasmic condensa-
tion (Kerr & Searle, 1973; Terada et al., 1989). The percent-
age of apoptotic cells was defined as the apoptotic index. To
analyse the apoptotic index of colon cancers, we selected
1,000, or more, cancer cells in the peripheral zone of the
tumour.
Statistical analysis
Results were analysed by the chi-square (x2) test or Fisher's
probability test (Siegel, 1956) or by one-way analysis of
variance with Dunn's multiple comparison (Siegel, 1956;
Snedecor & Cochran, 1967; Miller, 1966). Data are given as
means ± SE. 'Significant' indicates a calculated P value of
less than 0.05.
Results
Incidence, number and size ofcolon tumours
Ten rats in each group were sacrificed in week 9 for deter-
mination of serum gastrin levels and labelling indices of
colon mucosa. One rat in Group 1 and 2 rats in Group 2
died before week 31. No tumours were found in any of these
animals, which were excluded from the effective numbers.
One rat each from Groups 1 and 2 died in week 31 and 32,
respectively, which were included in the effective numbers. In
week 40, all rats that had received neurotensin had slightly,
but not significantly, lower body weight than the untreated
rats. The incidence, number and size of colon tumours in
each group are summarised in Table I. In Group 2 (olive oil
only), colon tumours were found in 15 (83%) of 18 rats
examined, the average number of tumours per rat being
1.3 ± 0.2. In Group 1 (neurotensin) the number of tumours
per rat, but not the incidence of colon tumours, was signifi-
cantly higher than in Group 2. Table I also shows that colon
tumours more than 10 mm in diameter were significantly
more frequent in Group 1 than in Group 2.
Histological types ofcolon tumours
Table II shows the histological types of a total of 62 colon
tumours in Groups 1 and 2. In Group 2 (olive oil only), 17
(71%) of the 24 tumours were adenocarcinomas, whereas in
Group 1 (neurotensin) the incidence of adenocarcinoma was
slightly, but not significantly, greater, being 82%. Table II
also shows the distribution of histological types of adenocar-
cinomas induced in AOM-treated rats. There was no
significant difference in the histopathological types of
adenocarcinomas between the two groups. The incidence of
colon adenocarcinomas penetrating muscle layer, or deeper,
was significantly greater in Group 1 than in Group 2.
Incidences of metastases of colon cancers to the peritoneum
and/or lymph nodes, or ear duct tumours, were slightly, but
not significantly, greater in Group 1 compared with Group 2.
Serum gastrin levels, labelling index and apoptotic index
Table III summarises data on the serum gastrin levels, the
labelling indices of the colon mucosa and cancers and the
apoptotic index of the colon cancers in each group in experi-
mental weeks 9 and/or 40. At both times examined, adminis-
tration of neurotensin in Group 1 had no influence on the
labelling indices of distal and proximal portions of the colon
mucosa. However, treatment with neurotensin significantly
increased the labelling index of colon cancers and decreased
the apoptotic index of colon cancers in week 40. At both
times examined, there was no significant difference in serum
gastrin levels between the two groups.
Discussion
In the present work, we found that prolonged alternate-day
administrastion of neurotensin in depot form significantly
increased the number and size but not the incidence of colon
tumours induced by AOM. This finding suggests that
neurotensin enhances the growth of colon tumours.
Neurotensin can act as a trophic factor on pancreas and
gastric antrum. Feurle et al. (1985, 1987) reported that long-
term neurotensin infusion led to a rise in protein concentra-
tion and to an increase in the thickness of the gastric antrum,
but that antral DNA concentration was not significantly
elevated. There has been no report on the effect of neuroten-
sin on the colon mucosa. However, more recently, Wood et
al. (1988) found that neurotensin caused dose-related in-
creases in weight and in DNA and protein content of small
intestine, but had no effect on weight, DNA, or protein
content of the colon. In the present work, we also found that
prolonged administration of neurotensin had no influence on
the labelling indices of distal and proximal portions of the370 M. TATSUTA et al.
Table I Incidences, numbers and size of colon tumours and body weights in AOM-treated rats
No. of colon
Body weight (g) Effective No. of rats No. of colon No. of Size of tumours more
Group ody weig g no. of with colon tumours per colon colon than 10mm
no. Treatmenta Initial 40 weeks rats tumours (%) rat tumours tumour (mm) in diameter (%)
1 Neurotensin 130± 1 390± 8 19 17 (89) 2.00.2b 38 9.5 1.4 14 (37)b
2 Olive oil 131 ± 1 398± 13 18 15 (83) 1.3±0.2 24 6.5 1.0 2 (8)
aTreatment regimens: Neurotensin, rats were given 10 weekly injections of 7.4mgkg-' of AOM, and were also given 200 tgkg-' of
neurotensin in depot form every other day until the end of the experiment; Olive oil, rats were given 10 weekly injections of 7.4 mg kg-' of
AOM, and were also given the vehicle, olive oil, only every other day until the end of the experiments. bSignificantly different from the value
for Group 2 at P<0.05.
Table II Histological type and/or depth of involvement of colon tumours and colon cancers
Colon tumour Adenocarcinoma
Depth of involvement (%)
Group Total Histological type (%) Total Histopathological type (%) Submucosal layer or
No. Treatmenta no. Adenoma Adenocarcinoma no. Group I Group 2 Group 3 layer deeper
I Neurotensin 38 7 (18) 31 (82) 31 4 (13) 12 (39) 15 (48) 11 (35) 20 (65)b
2 Olive oil 24 7 (29) 17 (71) 17 3 (17) 4 (24) 10 (59) 14 (82) 3 (18)
aFor explanation of treatments, see Table I. bSignificantly different from the value for Group 2 at P <0.05.
Table III Serum gastrin and labelling indices of colonic mucosa and cancers and apoptotic index of
colon cancer in AOM-treated rats
Serum Labelling index Apoptotic
week no. Treatmenta ga~StrinDuamPoia index of Experimental Group gastrin Distal Proximal Colon colon cancer
week no. Treatmenta (pgml-') portion portion cancer (%)
9 1 Neurotensin 315 ±45 0.31 ± 0.02 0.32 ± 0.02
2 Olive oil 311 39 0.31 0.01 0.32 0.02
40 1 Neurotensin 289 28 0.24 0.02 0.28 ±0.03 0.41 ±0.03b 2.0 0.2b
2 Olive oil 303 43 0.24 0.02 0.28 0.07 0.25 0.02 3.3 0.2
aFor explanation of treatments, see Table I. bSignificantly different from the value for Group 2 at
P <0.001.
colon. However, it significantly increased the labelling indices
of colon cancers. These findings indicate that enhancement
by neurotensin of colon carcinogenesis may be related to its
effect of increasing proliferation of colon cancer cells.
Although the mechanism(s) of this effect of neurotensin is
unknown, three possible explanations can be considered. The
first is the trophic action of gastrin. McGregor et al. (1982)
induced colon cancer in rats with methylazoxymethanol, and
found that chronic exposure to elevated serum gastrin levels
induced by antral exclusion augmented the size but not the
number of developing tumours. Svet-Moldavsky (1980)
reported that gastrin stimulated growth of transplanted
adenocarcinomas derived from colon, whereas growth of
other tumours, such as stomach sarcoma, hepatoma, sarcoma
of the rectum, and adenocarcinoma of the small intestinal
tract, was not affected. However, in the present work we
found that administration of neurotensin had no influence on
the serum gastrin level. A second possible explanation is the
effect of neurotensin on intracellular guanosine 3':5'-cyclic
monophosphate (cGMP). DeRubertis et al. (1976) found that
the cGMP content of human colon adenocarcinomas was
greater than that of the surrounding mucosa. Neurotensin
can increase intracellular cGMP concentration in some cell
lines (Amar et al., 1985). The third possibility is the effect of
neurotensin on activation of phosphatidylinositol turnover.
Amar et al. (1986) found that neurotensin had little effect on
cyclic nucleotide levels in the human colon adenocarcinoma
cell line HT29, but that it strongly stimulated phosphati-
dylinositol turnover. These results indicate that neurotensin
may regulate intracellular Ca"+ levels in HT29 cells by using
inositol triphosphate as a second messenger.
Our results show that neurotensin enhances the growth of
colon tumours. Although the exact mechanism(s) of this
effect requires further investigation, it may be related to the
enhancement by neurotensin of proliferation of colon cancer
cells.
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